Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (MERIT-1)

NCT02021292 PHASE2 COMPLETED Results posted

Study to evaluate if macitentan is efficient, safe and tolerable enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH).

Details

Lead sponsor	Actelion
Phase	PHASE2
Status	COMPLETED
Enrolment	80
Start date	Wed Aug 20 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Sep 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Chronic Thromboembolic Pulmonary Hypertension

Interventions

• Macitentan
• Placebo

Countries

France, Russia, Ukraine, Belgium, United Kingdom, Germany, Hungary, Mexico, Poland, South Korea, Lithuania, Switzerland, Thailand, China, Turkey (Türkiye), Czechia